share_log

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals' Da-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, And Lipid-Lowering Effects Compared to Survodutide, In Pre-Clinical Models

SEC ·  Jun 24 18:06
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.